PAVmed Acquires EsophaCap Manufacturer CapNostics

Acquires EsophaCap Manufacturer CapNostics LLC

YORK, October 7, 2021 (BUSINESS WIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or

"PAVmed"), a highly differentiated, multi-product, commercial-stage medical technology company, today announced a wholly

owned subsidiary of the Company has entered into a definitive membership interests purchase agreement with Martin Von Dyck, the sole

member and owner of North Carolina-based CapNostics, LLC, which manufactures EsophaCap -a U.S. FDA

510(k)-cleared and European CE Mark certified, non-endoscopic esophageal cell collection device which has been used in

pre-commercial clinical research of esophageal precancer biomarkers at major academic medical centers. Concurrently, the Company

entered into an exclusive long-term consulting agreement with Mr. Von Dyck, as well as an exclusive long-term manufacturing

agreement with the EsophaCap contract manufacturer.

entering this sector in 2018, PAVmed and its subsidiaries have aggressively sought to increase shareholder value by building a fully

integrated and expanding portfolio of products which broadly address early detection, monitoring and treatment of esophageal disease,"

said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. "Our major subsidiary, Lucid Diagnostics Inc., has

been focused on patients with gastroesophageal reflux disease ("GERD"), also known as chronic heartburn, who are at risk

of developing esophageal precancer and cancer. We believe Lucid's EsoCheck remains the only noninvasive esophageal cell collection

device capable of performing the anatomically targeted and protected sampling necessary to optimize diagnostic accuracy in these patients."

Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing

unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its

major subsidiary, Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer

and cancer - the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Its

GI Health division also includes the complementary EsoCure Esophageal Ablation Device with Caldus Technology. Another major

subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic

sensors and wireless communication to improve personalized cancer care through remote patient monitoring. Its Minimally Invasive Interventions

division markets its CarpX Minimally Invasive Device for Carpal Tunnel Syndrome. Other divisions include Infusion Therapy

(PortIO Implantable Intraosseous Vascular Access Device and NextFlo Intravenous Infusion Set), and Emerging Innovations

(non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information, please

majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn.

press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that

are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed's management,

are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties

that may cause such differences include, among other things, the ability to complete the initial public offering of Lucid; volatility

in the price of PAVmed's common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties

inherent in research and development, including the cost and time required advance PAVmed's products to regulatory submission;

whether regulatory authorities will be satisfied with the design of and results from PAVmed's preclinical studies; whether and

when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized;

our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other

regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business.

The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company's financial and

operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response.

New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible

to predict accurately and many of them are beyond PAVmed's control. For a further list and description of these and other important

risks and uncertainties that may affect PAVmed's future operations, see Part I, Item IA, "Risk Factors," in PAVmed's

most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item

1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims

any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in

events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results

will differ from those contained in the forward-looking statements.

Gallagher / Kristi Bruno

792-3937 / (617) 865-3940